PTPA gene loss occurs in 26% of malignant pleural mesothelioma patients and correlates with significantly decreased survival. When researchers restored PTPA expression in mesothelioma cells, it increased PP2A phosphatase activity, triggered oncogene-induced senescence through RAS pathway modulation, and enhanced carboplatin chemotherapy sensitivity. The mechanism involves PP2A-dependent dephosphorylation of Kinase Suppressor of Ras 1, leading to cellular stress responses including p53 activation and senescence markers. This finding illuminates a critical vulnerability in mesothelioma biology. The discovery that PTPA loss prevents oncogene-induced senescence—a natural tumor suppression mechanism—explains how cells escape normal growth controls to become malignant. More importantly, it identifies a biomarker-driven therapeutic strategy. The 26% of patients with PTPA loss represent a molecularly defined subgroup that could benefit from PP2A-targeted therapies or senolytic combinations. Given mesothelioma's notoriously poor prognosis and limited treatment options, this represents meaningful progress toward precision medicine approaches. However, translation will require validation in larger patient cohorts and development of effective PP2A modulators, as the tested compound ATUX-792 failed to replicate PTPA's senescence-inducing effects.